<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Mesenchymal-Stromal-Cell on 生物经济</title><link>https://cn.bioecon.ru/technologies/mesenchymal-stromal-cell/</link><description>Recent content in Mesenchymal-Stromal-Cell on 生物经济</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Mon, 20 Jul 2026 13:01:09 +0700</lastBuildDate><atom:link href="https://cn.bioecon.ru/technologies/mesenchymal-stromal-cell/index.xml" rel="self" type="application/rss+xml"/><item><title>干细胞治疗自身免疫病</title><link>https://cn.bioecon.ru/technology/stem-cell-therapy-autoimmune/</link><pubDate>Sat, 11 Jul 2026 00:00:00 +0000</pubDate><guid>https://cn.bioecon.ru/technology/stem-cell-therapy-autoimmune/</guid><description>输注间充质基质细胞（MSC）或调节性 T 细胞（Treg）以在自身免疫与炎性疾病中重建免疫耐受——这是一类以 Mesoblast 的 Ryoncil（类固醇难治性 GVHD）与 TiGenix 的 Alofisel（克罗恩瘘）为代表的获批资产类别，并在狼疮、关节炎与再生障碍性贫血上拥有更深厚的工程化 Treg 管线。</description></item></channel></rss>